(Q43679835)

English

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

scientific article published in March 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pancreatic adenocarcinoma

1 reference

based on heuristic

inferred from title

author name string

Hedy L Kindler

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Tatsuya Ioka

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Dirk J Richel

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Jaafar Bennouna

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Richard Létourneau

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Takuji Okusaka

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Akihiro Funakoshi

7

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Junji Furuse

8

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Young Suk Park

9

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Shinichi Ohkawa

10

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Gregory M Springett

11

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Harpreet S Wasan

12

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Peter C Trask

13

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Paul Bycott

14

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Alejandro D Ricart

15

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Sinil Kim

16

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Eric Van Cutsem

17

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

publication date

1 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

256-262

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970004-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970004-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Lessons learned in the management of advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970004-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970004-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970004-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970004-3

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970004-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970004-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970004-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970004-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970004-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970004-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trials in journal of clinical oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970004-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970004-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70004-3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43679835&oldid=2102473638"